EUVIMEDSkopri EUVIMED
Crossref

FGL1 Drives Epithelial–Mesenchymal Transition and Cisplatin Resistance in Laryngeal Squamous Cell Carcinoma

Shuang Teng iD, Meng Jin, Bing-Rui Yan, Ling-Mei Qu, Zhao-Nan Xu, Shuo Liu iD, Qiu-Ying Li, Feng-Shuo Zhang, Qing Hao, Shuang Guo, Rui Zhao iD, Ya-Nan Sun iD

Head & Neck · 2026-11-15

DOI: 10.1002/hed.70545 ↗

At a glance

Journal article in Head & Neck, published online on 2026-11-15. Written by Shuang Teng and 11 co-authors. Institution: Department of Otolaryngology, Head and Neck Surgery, Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, China. 20 references. Funded by: National Natural Science Foundation of China, Wuyuan Research Fund of the Fifth Affiliated Hospital of Harbin Medical University.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Fibrinogen‐like protein 1 (FGL1) is involved in tumor progression and immune regulation, but its role in laryngeal squamous cell carcinoma (LSCC) is unclear.

Methods

Plasma FGL1 levels were measured in 120 LSCC patients and 50 controls using ELISA. Tissue expression was analyzed via TCGA‐HNSC. Functional assays evaluated proliferation, migration, invasion, apoptosis, and cisplatin sensitivity. Prognostic value was assessed using survival and regression analyses.

Results

FGL1 was significantly elevated in LSCC plasma and tumor tissues. Functional studies showed that FGL1 promotes proliferation, migration, invasion, and EMT while inhibiting apoptosis and enhancing cisplatin resistance. Mechanistically, FGL1 knockdown increased Cleaved Caspase‐3 and decreased Bcl‐2 expression. High FGL1 levels were associated with poorer overall survival and independently predicted prognosis.

Conclusion

FGL1 promotes LSCC progression and chemoresistance, highlighting its potential as a circulating biomarker and therapeutic target.

Subjects

Author keywords

EMTFGL1LSCCapoptosisbiomarkerprognosis

Authors and institutions

  • Department of Otolaryngology, Head and Neck Surgery, Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, China.
  • Department of Otolaryngology, Head and Neck Surgery, Fifth Affiliated Hospital, Harbin Medical University, Daqing, Heilongjiang, China.

ORCID profiles: Shuang Teng, Shuo Liu, Rui Zhao, Ya-Nan Sun

Funding

  • National Natural Science Foundation of China
  • Wuyuan Research Fund of the Fifth Affiliated Hospital of Harbin Medical University

Cite

APA

Teng, S., Jin, M., Yan, B. R., Qu, L. M., Xu, Z. N., Liu, S., Li, Q. Y., Zhang, F. S., Hao, Q., Guo, S., Zhao, R., & Sun, Y. N. (2026). FGL1 Drives Epithelial–Mesenchymal Transition and Cisplatin Resistance in Laryngeal Squamous Cell Carcinoma. Head & Neck. https://doi.org/10.1002/hed.70545

Vancouver

Teng S, Jin M, Yan BR, Qu LM, Xu ZN, Liu S, et al. FGL1 Drives Epithelial–Mesenchymal Transition and Cisplatin Resistance in Laryngeal Squamous Cell Carcinoma. Head & Neck. 2026. doi:10.1002/hed.70545

BibTeX
@article{Teng2026,
  author = {Teng, Shuang and Jin, Meng and Yan, Bing-Rui and Qu, Ling-Mei and Xu, Zhao-Nan and Liu, Shuo and Li, Qiu-Ying and Zhang, Feng-Shuo and Hao, Qing and Guo, Shuang and Zhao, Rui and Sun, Ya-Nan},
  title = {FGL1 Drives Epithelial–Mesenchymal Transition and Cisplatin Resistance in Laryngeal Squamous Cell Carcinoma},
  journal = {Head & Neck},
  year = {2026},
  doi = {10.1002/hed.70545}
}
Start for free →